NASDAQ:BIVV Bioverativ Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Bioverativ Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $104.98 0.00 (0.00 %) (As of 03/19/2018) Add Share Today's Range$104.98Now: $104.98▼$104.9850-Day Range$104.98MA: $104.98▼$104.9852-Week Range$48.14Now: $104.98▼$105.01VolumeN/AAverage Volume3.03 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Bioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor thereby making the product last longer in a person's blood than various factor therapies. Its pipeline includes BIVV 001(rFVIIIFc-VWF-XTEN) and BIVV 002 (rFIXFc-XTEN).Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Bioverativ. Previous Next 2.6 Community Rank Outperform VotesBioverativ has received 279 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBioverativ has received 253 “underperform” votes. (Add your “underperform” vote.)Community SentimentBioverativ has received 52.44% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Bioverativ and other stocks. Vote “Outperform” if you believe BIVV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BIVV will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBioverativ does not currently pay a dividend.Dividend GrowthBioverativ does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bioverativ insiders have not sold or bought any company stock.Percentage Held by Institutions97.18% of the stock of Bioverativ is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.72 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorN/A Current SymbolNASDAQ:BIVV Previous Symbol CUSIPN/A CIK1681689 Webwww.bioverativ.com Phone+1-781-6634400Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable Receive BIVV News and Ratings via Email Sign-up to receive the latest news and ratings for BIVV and its competitors with MarketBeat's FREE daily newsletter. Bioverativ (NASDAQ:BIVV) Frequently Asked Questions How were Bioverativ's earnings last quarter? Bioverativ Inc (NASDAQ:BIVV) announced its quarterly earnings results on Thursday, October, 26th. The biotechnology company reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.25. The biotechnology company earned $291.60 million during the quarter, compared to analysts' expectations of $285.45 million. The firm's revenue was up 27.2% on a year-over-year basis. View Bioverativ's earnings history. What other stocks do shareholders of Bioverativ own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bioverativ investors own include Rexford Industrial Realty (REXR), Biogen (BIIB), Spark Therapeutics (ONCE), Marinus Pharmaceuticals (MRNS), Phillips 66 (PSX), Gilead Sciences (GILD), Verizon Communications (VZ), AbbVie (ABBV), BioMarin Pharmaceutical (BMRN) and Celgene (CELG). Who are Bioverativ's key executives? Bioverativ's management team includes the following people: Brian S. Posner, Independent Chairman of the Board (Age 55)John G. Cox, Chief Executive Officer, Director (Age 54)John T. Greene, Chief Financial Officer, Executive Vice President, Treasurer (Age 51)Rogerio Vivaldi Coelho M.D., Executive Vice President, Chief Global Therapeutic Operations Officer (Age 53)Lucia Celona, Executive Vice President, Chief Human Resources and Corporate Communications Officer (Age 51)Richard Brudnick, Executive Vice President - Business Development (Age 60)Andrea Marie DiFabio, Executive Vice President, Chief Legal Officer (Age 48)Diantha Duvall, Vice President - Finance, Chief Accounting Officer (Age 45)Alexander J. Denner Ph.D., Independent Director (Age 47)Louis J. Paglia, Independent Director (Age 59) What is Bioverativ's stock symbol? Bioverativ trades on the NASDAQ under the ticker symbol "BIVV." What is Bioverativ's stock price today? One share of BIVV stock can currently be purchased for approximately $104.98. What is Bioverativ's official website? The official website for Bioverativ is www.bioverativ.com. How can I contact Bioverativ? Bioverativ's mailing address is 225 2nd Ave, WALTHAM, MA 02451-1122, United States. The biotechnology company can be reached via phone at +1-781-6634400 or via email at [email protected] This page was last updated on 9/24/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
